NASDAQ:YTEN - Yield10 Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.87 -0.02 (-2.24 %)
(As of 05/21/2019 06:00 AM ET)
Previous Close$0.8899
Today's Range$0.86 - $0.9230
52-Week Range$0.68 - $1.85
Volume38,378 shs
Average Volume309,752 shs
Market Capitalization$10.88 million
P/E RatioN/A
Dividend YieldN/A
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.

Receive YTEN News and Ratings via Email

Sign-up to receive the latest news and ratings for YTEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous plastics products
SectorConsumer Staples
Current SymbolNASDAQ:YTEN



Sales & Book Value

Annual Sales$560,000.00
Book Value$0.50 per share


Net Income$-9,170,000.00
Net Margins-1,474.19%


Market Cap$10.88 million
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable

Yield10 Bioscience (NASDAQ:YTEN) Frequently Asked Questions

What is Yield10 Bioscience's stock symbol?

Yield10 Bioscience trades on the NASDAQ under the ticker symbol "YTEN."

When did Yield10 Bioscience's stock split? How did Yield10 Bioscience's stock split work?

Shares of Yield10 Bioscience reverse split on Tuesday, May 30th 2017. The 1-10 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Yield10 Bioscience stock prior to the reverse split would have 10 shares after the split.

How were Yield10 Bioscience's earnings last quarter?

Yield10 Bioscience Inc (NASDAQ:YTEN) posted its quarterly earnings results on Thursday, May, 9th. The specialty chemicals company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.01. The specialty chemicals company earned $0.12 million during the quarter. Yield10 Bioscience had a negative net margin of 1,474.19% and a negative return on equity of 126.91%. View Yield10 Bioscience's Earnings History.

When is Yield10 Bioscience's next earnings date?

Yield10 Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Yield10 Bioscience.

What price target have analysts set for YTEN?

2 analysts have issued twelve-month price objectives for Yield10 Bioscience's shares. Their forecasts range from $4.50 to $5.00. On average, they expect Yield10 Bioscience's share price to reach $4.75 in the next year. This suggests a possible upside of 445.4% from the stock's current price. View Analyst Price Targets for Yield10 Bioscience.

What is the consensus analysts' recommendation for Yield10 Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Yield10 Bioscience.

What are Wall Street analysts saying about Yield10 Bioscience stock?

Here are some recent quotes from research analysts about Yield10 Bioscience stock:
  • 1. According to Zacks Investment Research, "Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. " (5/18/2019)
  • 2. National Securities analysts commented, " First Quarter Results Meet Estimates. A net loss of $0.22 per share relative to consensus
    estimates of $0.23 per share, as well as a cash burn of $2.3 million, both fell in line with
    expectations. For the balance of 2019, we expect quarterly cash burn to remain in the $2.0 to
    $2.5 million range.
     Active Year for Field Trials Beginning. Several field trials are set to begin this spring for what
    we believe to be one of the most disruptive proprietary technologies in the agriculture industry.
    Most notable in our view is the C3003 field trial for canola, which represents the most significant
    market opportunity tested in the field to date. The C3004 field trial for camelina is also of
    significance given C3004’s seed yield enhancement in the lab of 26% to 65%, and the potential
    applicability to major row crops like corn and soybean. Results from these field trials are expected
    in late 2019 or early 2020.
     Major Commercial Partnerships Continuing. While details are not available due to
    confidentiality agreements, the research agreements with Bayer (STU: BAY – NR - €57.80) and
    Forage Genetics for analysis of YTEN traits are progressing. We believe it is likely that both
    companies will begin field trials in 2019. Of note is that we believe both companies have had
    sufficient time to conduct initial analysis, and we believe that if results were not of significance the
    partnerships would have been terminated. We view the ongoing status of both partnerships as
     Capital Raise Likely by Year End. With $6.1 million of cash on hand, we believe a capital raise
    is likely in coming quarters. This comes as no surprise, but we believe management is effectively
    controlling the cash burn while moving high value traits through development." (5/10/2019)
  • 3. Maxim Group analysts commented, "Yesterday, post-close, Yield10 reported 1Q19 results that were inline with expectations." (5/10/2019)

Has Yield10 Bioscience been receiving favorable news coverage?

Media headlines about YTEN stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Yield10 Bioscience earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave press coverage about the specialty chemicals company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.

Who are some of Yield10 Bioscience's key competitors?

What other stocks do shareholders of Yield10 Bioscience own?

Who are Yield10 Bioscience's key executives?

Yield10 Bioscience's management team includes the folowing people:
  • Dr. Oliver P. Peoples, Co-Founder, Pres, CEO & Director (Age 61)
  • Dr. Anthony J. Sinskey, Co-Founder & Director (Age 79)
  • Dr. Kristi Snell, VP of Research & Chief Science Officer (Age 51)
  • Ms. Lynne H. Brum, VP of Planning & Communications and Sec. (Age 55)
  • Mr. Charles B. Haaser, VP of Fin., Chief Accounting Officer & Treasurer (Age 63)

Who are Yield10 Bioscience's major shareholders?

Yield10 Bioscience's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.50%). View Institutional Ownership Trends for Yield10 Bioscience.

Which institutional investors are buying Yield10 Bioscience stock?

YTEN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Yield10 Bioscience.

How do I buy shares of Yield10 Bioscience?

Shares of YTEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Yield10 Bioscience's stock price today?

One share of YTEN stock can currently be purchased for approximately $0.8710.

How big of a company is Yield10 Bioscience?

Yield10 Bioscience has a market capitalization of $10.88 million and generates $560,000.00 in revenue each year. The specialty chemicals company earns $-9,170,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Yield10 Bioscience employs 22 workers across the globe.

What is Yield10 Bioscience's official website?

The official website for Yield10 Bioscience is

How can I contact Yield10 Bioscience?

Yield10 Bioscience's mailing address is 19 PRESIDENTIAL WAY, WOBURN MA, 01801. The specialty chemicals company can be reached via phone at 617-583-1700 or via email at [email protected]

MarketBeat Community Rating for Yield10 Bioscience (NASDAQ YTEN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  329
MarketBeat's community ratings are surveys of what our community members think about Yield10 Bioscience and other stocks. Vote "Outperform" if you believe YTEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe YTEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel